

Index of contents

0. Glossary

1. Introduction..... 3

1.1. *Gynaecological Cancers*4

1.1.1. Epithelial Ovarian Cancer4

1.1.2. Endometrial Cancer22

1.2. *Genomic Instability*36

1.2.1. Genomic Instability and cancer (leading causes) 36

1.2.2. Leading causes of genomic instability37

1.2.3. Clinical implications of genomic instability41

1.2.4. Methodological approaches to determine deficiencies in DDR pathways44

1.3. *In vitro cellular models*.....49

2. Hypothesis and main objectives 51

2.1. *Hypothesis*.....53

2.2. *Main objectives*.....53

3. Materials and methods 57

3.1. *Patients cohorts*59

3.1.1. COHORT 159

3.1.2. COHORT 262

3.1.3.	COHORT 3	66
3.1.4.	COHORT 4	70
3.2.	<i>Immunohistochemistry analysis</i>	73
3.3.	<i>Genomic approaches</i>	74
3.3.1.	DNA extraction, quantification and quality control 75	
3.3.2.	Truseq Low Input	76
3.3.3.	SureSelect XT HS +Oneseq Backbone 1 mb	77
3.3.4.	Microsatellite instability	79
3.3.5.	Sanger Sequencing	80
3.3.6.	Multiplex Ligation-dependent Probe Amplification 81	
3.4.	<i>Transcriptomic approaches</i>	82
3.4.1.	HTG Oncology Biomarker Panel	82
3.5.	<i>Bioinformatics Analysis</i>	85
3.5.1.	Copy-Number Variation pipelines	85
3.5.2.	Data mining in OC cohort	89
3.5.3.	Random Forest Algorithm	94
3.6.	<i>In vitro studies</i>	95
3.6.1.	Cell lines and culturing	96
3.6.2.	Treatment schemes, drug-sensitivity assays and combination treatment.....	97
3.7.	<i>In vitro data processing</i>	106

3.8. <i>Statistics</i>	106
3.8.1. Descriptive statistics	106
3.8.2. Parameters of clinical response	106
3.8.3. Survival analysis	108
4. Results	109
4.1. <i>Characterization of genomic Instability</i>	111
4.1.1. Establishing the basis of GI: tuning methodological and analytical approaches.....	111
4.1.2. Multi-gene NGS panel to determine HRD and clinical impact of molecular classification.....	111
4.1.3. Predictive model fitting and validation to predict response to DNA-damaging agents.....	124
4.1.4. Another clinical scenario: POLA phase II cohort	133
4.1.5. OC Cell line Panel.....	141
4.2. <i>12g prognostic model in EC cohort</i>	146
4.2.1. Selection of the multigene-NGS panel and mutational analysis	146
4.2.2. Impact of 12 genes RF model in the clinical stratification of the disease.....	153
4.2.3. CNV-based classification: Validation of the 12g model	158
4.2.4. Expression analysis	161
4.3. <i>In vitro characterization</i>	165

4.3.1. Drug-sensitivity analysis of ovarian Cancer cell lines: IC50 calculation.....	165
4.3.2. Generation of PM01183-Resistant cell line and functional characterization	170
5. Discussion.....	177
6. Conclusions.....	209
7. References.....	213
Annexes	237
<i>Annexed data</i>	<i>239</i>
<i>Annexed papers</i>	<i>275</i>